Abattis Bioceuticals Corp
Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cann… Read more
Market Cap & Net Worth: Abattis Bioceuticals Corp (ATTBF)
Abattis Bioceuticals Corp (PINK:ATTBF) has a market capitalization of $47.78K ($47.78K) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #44379 globally and #14078 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Abattis Bioceuticals Corp's stock price $0.00 by its total outstanding shares 477804139 (477.80 Million).
Abattis Bioceuticals Corp Market Cap History: 2015 to 2025
Abattis Bioceuticals Corp's market capitalization history from 2015 to 2025. Data shows change from $22.98 Million to $47.78K (-46.90% CAGR).
Abattis Bioceuticals Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Abattis Bioceuticals Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.02x
Abattis Bioceuticals Corp's market cap is 6.02 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $22.98 Million | $91.94K | -$4.47 Million | 249.97x | N/A |
| 2018 | $25.85 Million | $8.37K | -$78.01 Million | 3087.95x | N/A |
| 2019 | $2.15 Million | $356.88K | -$3.04 Million | 6.02x | N/A |
Competitor Companies of ATTBF by Market Capitalization
Companies near Abattis Bioceuticals Corp in the global market cap rankings as of March 18, 2026.
Key companies related to Abattis Bioceuticals Corp by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Abattis Bioceuticals Corp Historical Marketcap From 2015 to 2025
Between 2015 and today, Abattis Bioceuticals Corp's market cap moved from $22.98 Million to $ 47.78K, with a yearly change of -46.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $47.78K | 0.00% |
| 2024 | $47.78K | 0.00% |
| 2023 | $47.78K | 0.00% |
| 2022 | $47.78K | 0.00% |
| 2021 | $47.78K | -99.20% |
| 2020 | $5.97 Million | +177.78% |
| 2019 | $2.15 Million | -91.68% |
| 2018 | $25.85 Million | -87.31% |
| 2017 | $203.69 Million | +285.79% |
| 2016 | $52.80 Million | +129.73% |
| 2015 | $22.98 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Abattis Bioceuticals Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $47.78K USD |
| MoneyControl | $47.78K USD |
| MarketWatch | $47.78K USD |
| marketcap.company | $47.78K USD |
| Reuters | $47.78K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.